Barrett's esophagus: proton pump inhibitors and chemoprevention II

Ann N Y Acad Sci. 2011 Sep:1232:114-39. doi: 10.1111/j.1749-6632.2011.06048.x.

Abstract

The following on proton pump inhibitors (PPIs) and chemoprevention in relation to Barrett's esophagus includes commentaries on 48-h pH monitoring, pH-impedence, bile acid testing, dyspepsia, long/short segment Barrett's esophagus, nonerosive reflux disease (NERD), functional heartburn, dual-release delivery PPIs, immediate-release PPIs, long-term PPI use, prokinetic agents, obesity, baclofen, nocturnal acid breakthrough, nonsteroidal anti-inflammatory drugs (NSAIDs), and new PPIs.

MeSH terms

  • Barrett Esophagus / drug therapy*
  • Chemoprevention*
  • Humans
  • Monitoring, Physiologic
  • Proton Pump Inhibitors / therapeutic use*
  • Treatment Outcome

Substances

  • Proton Pump Inhibitors